Halozyme Therapeutics (NASDAQ:HALO) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report released on Wednesday, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on HALO. TD Cowen initiated coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an outperform rating and a $54.00 price target for the company. JMP Securities reissued a market outperform rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. Benchmark restated a buy rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. StockNews.com upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Friday, February 23rd. Finally, The Goldman Sachs Group lowered their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a neutral rating on the stock in a research note on Thursday, January 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $53.29.

Halozyme Therapeutics Stock Up 2.2 %

Halozyme Therapeutics stock opened at $38.64 on Wednesday. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 1-year low of $29.85 and a 1-year high of $45.00. The company has a fifty day simple moving average of $39.56 and a 200 day simple moving average of $37.77. The company has a market cap of $4.91 billion, a P/E ratio of 18.31, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Research analysts anticipate that Halozyme Therapeutics will post 3.45 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 30,000 shares of company stock valued at $1,196,800 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of large investors have recently made changes to their positions in the company. TD Asset Management Inc grew its holdings in Halozyme Therapeutics by 517.0% in the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after buying an additional 1,662,390 shares in the last quarter. Norges Bank bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $44,935,000. Epoch Investment Partners Inc. grew its stake in shares of Halozyme Therapeutics by 250.5% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after acquiring an additional 831,199 shares in the last quarter. Macquarie Group Ltd. grew its stake in shares of Halozyme Therapeutics by 22.8% in the first quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after acquiring an additional 595,220 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Halozyme Therapeutics by 174.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after acquiring an additional 563,989 shares during the period. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.